NeuroOne Medical Technologies (NASDAQ:NMTC) Issues Quarterly Earnings Results

NeuroOne Medical Technologies (NASDAQ:NMTC) announced its quarterly earnings results on Tuesday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01, FiscalAI reports. NeuroOne Medical Technologies had a negative return on equity of 74.69% and a negative net margin of 29.81%.The company had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Revenue guidance of at least $10.5 million for FY2026, a stated minimum 17% increase year‑over‑year, and management says the company is funded through fiscal 2026 (subject to hitting key milestones).
• The OneRF brain ablation system showed accelerating adoption — Q1 ablations were nearly half of all procedures since launch — and the company plans a registry with first patient enrollment targeted by the end of Q3.
• The OneRF trigeminal nerve system has FDA 510(k) clearance, completed a limited launch with nine patients at three centers who are reported pain‑free, and the limited launch is expected to finish by end of Q2 while strategic licensing discussions continue.
• Financials show a Q1 net loss of $1.4 million (vs. prior‑year income that included a $3 million license payment), no license revenue this quarter, and cash down to $3.6 million from $6.6 million, leaving a limited runway despite being “funded through fiscal 2026.”
• Pipeline progress accelerated — drug‑delivery devices are expected to be available for investigational/animal use in Q3 (about six months earlier than planned), animal studies for the percutaneous paddle electrode are starting soon, and basivertebral nerve work is advancing with advisory boards and partnership discussions.

NeuroOne Medical Technologies Stock Performance

NMTC opened at $0.68 on Wednesday. The company has a market capitalization of $34.24 million, a PE ratio of -8.49 and a beta of 0.71. The stock’s fifty day moving average is $0.81 and its 200-day moving average is $0.80. NeuroOne Medical Technologies has a one year low of $0.40 and a one year high of $1.25.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sio Capital Management LLC bought a new stake in NeuroOne Medical Technologies during the second quarter worth approximately $2,390,000. Vanguard Group Inc. lifted its position in shares of NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth $143,000. Virtu Financial LLC acquired a new position in shares of NeuroOne Medical Technologies in the 3rd quarter worth $88,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of NeuroOne Medical Technologies in the 1st quarter worth $84,000. 16.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $2.23.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.